Cargando…

Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate

BACKGROUND: The aim of this study was to develop the near infrared fluorescence (NIRF)-based imaging agent for the visualization of vascular endothelial growth factor (VEGF) in colon cancer. AlexaFluor 750 conjugating with bevacizumab, and injected intravenously into nude mice bearing VEGF over-expr...

Descripción completa

Detalles Bibliográficos
Autores principales: Paudyal, Bishnuhari, Paudyal, Pramila, Shah, Dilip, Tominaga, Hideyuki, Tsushima, Yoshito, Endo, Keigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012715/
https://www.ncbi.nlm.nih.gov/pubmed/24780003
http://dx.doi.org/10.1186/1423-0127-21-35
_version_ 1782314961064689664
author Paudyal, Bishnuhari
Paudyal, Pramila
Shah, Dilip
Tominaga, Hideyuki
Tsushima, Yoshito
Endo, Keigo
author_facet Paudyal, Bishnuhari
Paudyal, Pramila
Shah, Dilip
Tominaga, Hideyuki
Tsushima, Yoshito
Endo, Keigo
author_sort Paudyal, Bishnuhari
collection PubMed
description BACKGROUND: The aim of this study was to develop the near infrared fluorescence (NIRF)-based imaging agent for the visualization of vascular endothelial growth factor (VEGF) in colon cancer. AlexaFluor 750 conjugating with bevacizumab, and injected intravenously into nude mice bearing VEGF over-expressing HT29 human colorectal cancer. Optical imaging was performed at 15 min, 24 h and 48 h post injection. Immunofluorescences staining of the tumor sections were performed. HT29 colorectal cancer xenografts were clearly visualized with bevacizumab-AlexaFluor 750. RESULTS: Ex vivo analysis showed 2.1 ± 0.4%, 37.6 ± 6.3% and 38.5 ± 6.2% injected dose/g accumulated in the tumors at 15 min, 24 h and 48 h respectively. Tumor uptake was significantly decreased in pretreated with excess of bevacizumab (p = 0.002). Immunofluorescence analysis showed strong staining of anti-CD 31 antibody around the blood vessels. Anti-VEGF-A and bevacizumab showed heterogeneous expression throughout the tumor. CONCLUSIONS: Current study successfully detected the VEGF expression in HT29 colorectal cancer xenografts, signifying as a potential agent for non-invasive imaging of VEGF expression, which may be applied in clinical practice.
format Online
Article
Text
id pubmed-4012715
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40127152014-05-08 Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate Paudyal, Bishnuhari Paudyal, Pramila Shah, Dilip Tominaga, Hideyuki Tsushima, Yoshito Endo, Keigo J Biomed Sci Research BACKGROUND: The aim of this study was to develop the near infrared fluorescence (NIRF)-based imaging agent for the visualization of vascular endothelial growth factor (VEGF) in colon cancer. AlexaFluor 750 conjugating with bevacizumab, and injected intravenously into nude mice bearing VEGF over-expressing HT29 human colorectal cancer. Optical imaging was performed at 15 min, 24 h and 48 h post injection. Immunofluorescences staining of the tumor sections were performed. HT29 colorectal cancer xenografts were clearly visualized with bevacizumab-AlexaFluor 750. RESULTS: Ex vivo analysis showed 2.1 ± 0.4%, 37.6 ± 6.3% and 38.5 ± 6.2% injected dose/g accumulated in the tumors at 15 min, 24 h and 48 h respectively. Tumor uptake was significantly decreased in pretreated with excess of bevacizumab (p = 0.002). Immunofluorescence analysis showed strong staining of anti-CD 31 antibody around the blood vessels. Anti-VEGF-A and bevacizumab showed heterogeneous expression throughout the tumor. CONCLUSIONS: Current study successfully detected the VEGF expression in HT29 colorectal cancer xenografts, signifying as a potential agent for non-invasive imaging of VEGF expression, which may be applied in clinical practice. BioMed Central 2014-04-29 /pmc/articles/PMC4012715/ /pubmed/24780003 http://dx.doi.org/10.1186/1423-0127-21-35 Text en Copyright © 2014 Paudyal et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Paudyal, Bishnuhari
Paudyal, Pramila
Shah, Dilip
Tominaga, Hideyuki
Tsushima, Yoshito
Endo, Keigo
Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate
title Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate
title_full Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate
title_fullStr Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate
title_full_unstemmed Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate
title_short Detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate
title_sort detection of vascular endothelial growth factor in colon cancer xenografts using bevacizumab based near infrared fluorophore conjugate
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012715/
https://www.ncbi.nlm.nih.gov/pubmed/24780003
http://dx.doi.org/10.1186/1423-0127-21-35
work_keys_str_mv AT paudyalbishnuhari detectionofvascularendothelialgrowthfactorincoloncancerxenograftsusingbevacizumabbasednearinfraredfluorophoreconjugate
AT paudyalpramila detectionofvascularendothelialgrowthfactorincoloncancerxenograftsusingbevacizumabbasednearinfraredfluorophoreconjugate
AT shahdilip detectionofvascularendothelialgrowthfactorincoloncancerxenograftsusingbevacizumabbasednearinfraredfluorophoreconjugate
AT tominagahideyuki detectionofvascularendothelialgrowthfactorincoloncancerxenograftsusingbevacizumabbasednearinfraredfluorophoreconjugate
AT tsushimayoshito detectionofvascularendothelialgrowthfactorincoloncancerxenograftsusingbevacizumabbasednearinfraredfluorophoreconjugate
AT endokeigo detectionofvascularendothelialgrowthfactorincoloncancerxenograftsusingbevacizumabbasednearinfraredfluorophoreconjugate